Clinical features of anti-neurofascin-155 antibody positive autoimmune nodopathy in 6 children

Objective: To analyze the clinical features of anti-neurofascin-155 (NF155) antibody positive autoimmune nodopathy in children. Methods: This was a case series study. A total of 6 children who were diagnosed accurately as anti-NF155 antibody positive autoimmune nodopathy by cell immunofluorescence a...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 62(2024), 8 vom: 02. Aug., Seite 780-785
1. Verfasser: Fang, Z X (VerfasserIn)
Weitere Verfasser: Zhang, M, Hu, C P, Zhou, Y F, Zhang, Y J, Yu, L F, Wang, Y, Zhou, S Z
Format: Online-Aufsatz
Sprache:Chinese
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:English Abstract Journal Article NFASC protein, human Autoantibodies Nerve Growth Factors Cell Adhesion Molecules
LEADER 01000caa a22002652 4500
001 NLM375274669
003 DE-627
005 20240801233557.0
007 cr uuu---uuuuu
008 240723s2024 xx |||||o 00| ||chi c
024 7 |a 10.3760/cma.j.cn112140-20240228-00130  |2 doi 
028 5 2 |a pubmed24n1488.xml 
035 |a (DE-627)NLM375274669 
035 |a (NLM)39039882 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Fang, Z X  |e verfasserin  |4 aut 
245 1 0 |a Clinical features of anti-neurofascin-155 antibody positive autoimmune nodopathy in 6 children 
264 1 |c 2024 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 29.07.2024 
500 |a Date Revised 31.07.2024 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Objective: To analyze the clinical features of anti-neurofascin-155 (NF155) antibody positive autoimmune nodopathy in children. Methods: This was a case series study. A total of 6 children who were diagnosed accurately as anti-NF155 antibody positive autoimmune nodopathy by cell immunofluorescence assay at the Children's Hospital of Fudan University from January 2020 to December 2023 were collected. This study retrospectively analyzed 6 pediatric children's clinical manifestations, laboratory and electrophysiological examination results, and treatment outcomes. Results: Among 6 children with anti-NF155 antibody positive autoimmune nodopathy, there were 4 boys and 2 girls. The onset age of 6 children ranged from 3 years and 8 months to 12 years. All 6 children had extremity weakness (more severe in the distal and the lower extremities than in the upper extremities), 5 children had sensory deficits such as numbness or pain in the extremities, 4 children had tremors and ataxia, 3 children had cranial nerve involvement. Among the 6 children, 4 children had protein-cell separation in cerebrospinal fluid examinations. Among the 6 children, 1 child had central nervous system demyelination, the brain magnetic resonance imaging showed multiple abnormal signals in the bilateral cerebral hemispheres. Four children showed motor and sensory nerve damage in electrophysiological examination, and 2 children only showed motor nerve damage. Three children showed myelin and axonal damage, and 3 children only showed axonal damage. Among the 6 children, 5 children were treated with intravenous immunoglobulin and steroids. Among them, 2 children underwent plasma exchange due to poor efficacy, and subsequently, rituximab was added. There was 1 child changed the treatment with olfatomumab since the symptoms did not significantly improve after using rituximab. After treatment for 4-15 months, 2 children had no clinical symptoms, 1 child had improvement in clinical symptoms, 2 children had no significant improvement in clinical symptoms, and 1 child who did not receive the immunotherapy had no significant change in clinical symptoms. Conclusions: Anti-NF155 antibody positive autoimmune nodopathy in children presents with varying degrees of clinical manifestations. It is mainly characterized by extremity weakness, numbness and pain, often accompanied bytremorsand ataxia. Some pediatric patients may also have central nervous system demyelination. Cerebrospinal fluid and electrophysiological examination are important auxiliary examination methods. If steroid therapy is not effective, plasma exchange and rituximab treatment should be used as soon as possible 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a NFASC protein, human  |2 NLM 
650 7 |a Autoantibodies  |2 NLM 
650 7 |a Nerve Growth Factors  |2 NLM 
650 7 |a Cell Adhesion Molecules  |2 NLM 
700 1 |a Zhang, M  |e verfasserin  |4 aut 
700 1 |a Hu, C P  |e verfasserin  |4 aut 
700 1 |a Zhou, Y F  |e verfasserin  |4 aut 
700 1 |a Zhang, Y J  |e verfasserin  |4 aut 
700 1 |a Yu, L F  |e verfasserin  |4 aut 
700 1 |a Wang, Y  |e verfasserin  |4 aut 
700 1 |a Zhou, S Z  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 62(2024), 8 vom: 02. Aug., Seite 780-785  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:62  |g year:2024  |g number:8  |g day:02  |g month:08  |g pages:780-785 
856 4 0 |u http://dx.doi.org/10.3760/cma.j.cn112140-20240228-00130  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 62  |j 2024  |e 8  |b 02  |c 08  |h 780-785